A
B
IFNy+ (% of
CD4+ population)
TNFa+ (% of CD4+ population)
C
CD4+ population)
**
50
100
**
80
*
**
IL-2+ (% of
*
40
80
60
30
60
20
40
10
20
20
O
CD69
CD69 CD103 CD69*CD103
0
CD69
CD69*CD103
CD69*CD103
O
CD69
CD69 CD103
CD69 CD103
D
T
IL-10+ (% of CD4+ population)
**
20
CD39+ (% of
CD4+ population)
100
**
PD-1+ (% of
CD4+ population)
100
1
15
80
80
11.4444
O
60
5
20
40
A
0
20
CD69
CD69 CD103 CD69 CD103
CD69
CD69 CD103 CD69 CD103
O
CD69
CD69 CD103
CD69 CD103
6
CTLA-4+ (% of CD4+ population)
80-
60
20
O
CD69
CD69 CD103 CD69 CD103
Supplementary Figure 5. Characterization of CD4+CD69+CD103+ T cells in cSCC. (A-G) Graphs showing expression of (A) IFNy (n=14 tumors), (B) TNFa (n=11 tumors), (C) IL-2 (n=11 tumors), (D) IL-10 (n=10 tumors), (E) CD39 (n=14 tumors), (F) PD-1 (n=11 tumors) and (G) CTLA-4 (n=14 tumors) by the tumoral CD4+CD69-, CD4+CD69+CD103- and CD4+CD69+CD103+ T cell populations. Expression of cytokines was determined following stimulation in vitro with PMA and ionomycin for 5 hours. Horizontal bars = means, *p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.